Literature DB >> 6752715

Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases.

T W Smith, V P Butler, E Haber, H Fozzard, F I Marcus, W F Bremner, I C Schulman, A Phillips.   

Abstract

Purified Fab fragments of digoxin-specific antibodies obtained from sheep were used to treat 26 patients with advanced, life-threatening digoxin (23 cases) or digitoxin (3 cases) toxicity. These patients had advanced cardiac arrhythmias, and in some cases hyperkalemia, which were resistant to conventional treatment. All patients had an initial favorable response to doses of Fab fragments calculated (in most cases) to be equivalent, on a molar basis, to the amount of cardiac glycoside in the patient's body. In four patients treated after prolonged hypotension and low cardiac output, death ensued from cerebral or myocardial hypoperfusion. In one case the available Fab fragment supply was inadequate to reverse a massive suicidal ingestion of digoxin, and the patient died after recurrent ventricular arrhythmias. In the remaining 21 patients, cardiac rhythm disturbances and hyperkalemia were rapidly reversed, and full recovery ensued. There were no adverse reactions to the treatment. We conclude that the use of purified digoxin-specific Fab fragments is a safe and effective means to reverse advanced, life-threatening digitalis intoxication.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6752715     DOI: 10.1056/NEJM198211253072201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  35 in total

1.  Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats.

Authors:  J J Hubbard; E M Laurenzana; D K Williams; W B Gentry; S M Owens
Journal:  Int Immunopharmacol       Date:  2011-10-12       Impact factor: 4.932

Review 2.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

3.  An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop.

Authors:  Sean W Fanning; James R Horn
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

4.  Lethal ingestion of Chinese herbal tea containing ch'an su.

Authors:  R J Ko; M S Greenwald; S M Loscutoff; A M Au; B R Appel; R A Kreutzer; W F Haddon; T Y Jackson; F O Boo; G Presicek
Journal:  West J Med       Date:  1996-01

5.  Digoxin toxicity in a premature infant: treatment with Fab fragments of digoxin-specific antibodies.

Authors:  S Presti; D Friedman; J Saslow; E F Doyle; V P Butler; T W Smith; E Haber
Journal:  Pediatr Cardiol       Date:  1985       Impact factor: 1.655

6.  Severe digoxin intoxication in a child treated by infusion of digoxin-specific Fab-antibody-fragments.

Authors:  R Rossi; J U Leititis; K J Hagel; A Smolarz; M Brandis
Journal:  Eur J Pediatr       Date:  1984-06       Impact factor: 3.183

7.  Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure.

Authors:  Frédéric Lapostolle; Stephen W Borron; Carine Verdier; Fabrice Arnaud; James Couvreur; Bruno Mégarbane; Frédéric Baud; Frédéric Adnet
Journal:  Intensive Care Med       Date:  2008-04-04       Impact factor: 17.440

Review 8.  Immunotherapy in the poisoned patient. Overview of present applications and future trends.

Authors:  J B Sullivan
Journal:  Med Toxicol       Date:  1986 Jan-Feb

9.  The influence of digoxin antibodies on digoxin disposition and effect: studies in guinea-pigs and HeLa cells.

Authors:  N M Griffiths; D S Hewick; J F Lamb; I H Stevenson
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

Review 10.  Potassium and anaesthesia.

Authors:  J E Tetzlaff; J F O'Hara; M T Walsh
Journal:  Can J Anaesth       Date:  1993-03       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.